Janux Therapeutics Appoints William Go as Chief Medical Officer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Janux Therapeutics announced that William Go has been appointed chief medical officer, effective January 26. Go succeeds Zachariah McIver, who will be leaving the company to pursue other opportunities. Most recently Go served as CMO at A2 Biotherapeutics.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on JANX
Wall Street analysts forecast JANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JANX is 55.25 USD with a low forecast of 25.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.950
Low
25.00
Averages
55.25
High
150.00
Current: 13.950
Low
25.00
Averages
55.25
High
150.00
About JANX
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Janux Therapeutics and Bristol Myers Squibb Sign $800 Million Collaboration Agreement
- Collaboration Agreement: Janux Therapeutics has entered into an exclusive worldwide license agreement with Bristol Myers Squibb, receiving up to $50 million in upfront and near-term milestone payments, with potential total payments reaching approximately $800 million, significantly enhancing its capabilities in developing tumor immunotherapies.
- Clinical Development Support: The collaboration allows Janux to complete preclinical development up to Investigational New Drug (IND) submission, while Bristol Myers Squibb will take charge of subsequent development and commercialization, expected to accelerate the market introduction of new drugs.
- Positive Market Reaction: Following the announcement of the agreement, Janux's stock rose by 7.69% to $14.29, despite a 66.97% decline over the past 12 months, indicating that the collaboration is seen as a strong validation of its tumor-activated platform, potentially improving investor confidence.
- Optimistic Analyst Ratings: Although Clear Street downgraded its rating to Hold with a target price of $12.00, the overall analyst consensus remains a Buy with an average target price of $61.76, reflecting market confidence in Janux's future development.
Continue Reading
Janux Therapeutics (JANX) Partners with Bristol Myers Squibb for Tumor-Activated Therapy Development
- Strategic Collaboration: Janux Therapeutics has entered a partnership with Bristol Myers Squibb to focus on a yet-to-be-disclosed solid tumor target across multiple cancer types, aiming to expand treatment options for patients globally and enhance the company's market position in oncology.
- Development Management Division: Under the agreement, Janux will handle preclinical development through IND submission, while Bristol Myers Squibb will hold the IND and oversee subsequent clinical development and global commercialization, ensuring efficient resource utilization and specialized management.
- Positive Market Reaction: Following the announcement, Janux Therapeutics' stock traded over 8% higher in Thursday's premarket, reflecting market optimism regarding the collaboration's prospects, which may enhance the company's future fundraising capabilities and investor confidence.
- Global Commercialization Potential: This partnership not only strengthens Janux's R&D capabilities in oncology but also provides Bristol Myers Squibb with a new product line, expected to drive both companies' competitiveness and market share in the global market.
Continue Reading